<DOC>
	<DOCNO>NCT01999686</DOCNO>
	<brief_summary>This 3-arm , randomize , double-blind , double-dummy , control clinical study 6 month treatment evaluate metabolic clinical efficacy well safety DLBS3233 alone , metformin combination , improve metabolic reproductive parameter .</brief_summary>
	<brief_title>PCOS Treatment Using DLBS3233 , Metformin , Combination Both</brief_title>
	<detailed_description>There 3 group treatment ( N = 186 ) , consist 62 subject , follow : - Treatment I : DLBS3233 100 mg daily - Treatment II : Metformin XR 750 mg twice daily - Treatment III : DLBS3233 100 mg daily Metformin XR 750 mg twice daily . Laboratory examination evaluate metabolic efficacy parameter perform baseline , Month 3rd , end study ( Month 6th ) . Clinical laboratory examination evaluate reproductive efficacy parameter use trans-vaginal USG biomarkers ( reproductive hormone ) perform baseline end study . Safety examination perform baseline end study . Occurrence adverse event observe along study conduct .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Signed write informed consent prior participation study . 2 . Female subject reproductive age ( i.e . 1840 year ) willing conceive . 3 . Subject diagnosis polycystic ovary syndrome confirm two follow ( Rotterdam Criteria ) : Hyperandrogenism ( define elevate free testosterone concentration ; FerrimanGallwey Score ≥ 8 ) . Ovarian dysfunction indicate menstrual irregularity : oligomenorrhea ( cycle &gt; 35 day ) , amenorrhea ( menses last 3 month ) negative screen pregnancy test . Polycystic ovary show ultrasonography ( USG ) . 4 . Subject insulin resistance define : HOMAIR &gt; 2.00 . 5 . Subject body mass index ( BMI ) 1935 inclusive . 6 . Able take oral medication . 1 . Pregnant lactate woman ( urinary pregnancy test apply screen ) . 2 . Based previous current medical ( either laboratory clinical ) examination , subject know follow condition : Cushing 's syndrome , late onset congenital adrenal hyperplasia , androgensecreting tumor , uncontrolled thyroid disease , hyperprolactinemia . 3 . Known follow medical condition : Diabetes mellitus , Uncontrolled hypertension Symptomatic cardiovascular disease : Acute chronic infection baseline . Any known malignancy . 4 . History gynecological surgery . 5 . Impaired renal function 6 . Impaired liver function 7 . Medicallyassisted weight loss medication surgical procedure . 8 . Currently laparoscopic ovarian diathermy ( LOD ) . 9 . Currently treatment vitro fertilization ( IVF ) technique . 10 . Have regularly take follow medication , within ≤ 3 month prior screen , : Clomiphene citrate Insulin sensitizer , i.e . metformin thiazolidinediones Aromatase inhibitor , : anastrozole , letrozole Glucocorticoids Gonadotropins Gonadotropinreleasing hormone agonist ( GnRHa ) Oral contraceptive pill ( OCPs ) Antiandrogens , : spironolactone , cyproterone acetate ( CPA ) , flutamide Any traditional herbal medicine 11 . Participating clinical trial within 30 day prior screen .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Polycystic ovarium syndrome</keyword>
	<keyword>DLBS3233</keyword>
	<keyword>metformin</keyword>
	<keyword>insulin resistance</keyword>
	<keyword>Female</keyword>
</DOC>